Finnish (OMX) Market Analysis & Valuation

Market Valuation and Performance

Has the Finnish Market valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 04 Jun 2026	€378.4b	€196.7b	€15.6b	19.1x	24.3x	1.9x
Sat, 02 May 2026	€353.5b	€197.1b	€16.0b	18.4x	22.1x	1.8x
Mon, 30 Mar 2026	€321.3b	€196.1b	€15.2b	18.7x	21.1x	1.6x
Wed, 25 Feb 2026	€340.9b	€196.6b	€15.1b	19.8x	22.6x	1.7x
Fri, 23 Jan 2026	€333.6b	€197.7b	€13.4b	20x	24.9x	1.7x
Sun, 21 Dec 2025	€316.4b	€197.3b	€13.4b	19x	23.6x	1.6x
Tue, 18 Nov 2025	€306.3b	€197.1b	€13.4b	18.8x	22.9x	1.6x
Thu, 16 Oct 2025	€292.6b	€197.6b	€13.3b	19.8x	22x	1.5x
Sat, 13 Sep 2025	€289.5b	€196.1b	€13.2b	20.7x	21.9x	1.5x
Mon, 11 Aug 2025	€281.9b	€196.5b	€13.3b	20.7x	21.2x	1.4x
Wed, 09 Jul 2025	€277.6b	€196.1b	€13.5b	20.4x	20.6x	1.4x
Fri, 06 Jun 2025	€275.2b	€196.1b	€13.5b	20x	20.4x	1.4x
Sun, 04 May 2025	€264.0b	€196.0b	€13.7b	19.9x	19.3x	1.3x
Tue, 01 Apr 2025	€260.3b	€195.1b	€14.6b	19.4x	17.8x	1.3x
Thu, 27 Feb 2025	€275.3b	€195.4b	€14.6b	19.6x	18.8x	1.4x
Sat, 25 Jan 2025	€258.9b	€199.2b	€14.7b	18x	17.6x	1.3x
Mon, 23 Dec 2024	€243.7b	€199.2b	€14.7b	17.4x	16.5x	1.2x
Wed, 20 Nov 2024	€249.0b	€199.9b	€14.7b	17.9x	16.9x	1.2x
Fri, 18 Oct 2024	€264.9b	€199.7b	€14.6b	18.2x	18.2x	1.3x
Sun, 15 Sep 2024	€220.7b	€188.3b	€9.6b	18.4x	23.1x	1.2x
Tue, 13 Aug 2024	€216.9b	€188.7b	€9.9b	17.9x	22x	1.1x
Thu, 11 Jul 2024	€219.9b	€190.2b	€10.1b	18.6x	21.7x	1.2x
Sat, 08 Jun 2024	€227.5b	€191.0b	€10.0b	18.9x	22.8x	1.2x
Mon, 06 May 2024	€222.4b	€190.9b	€10.0b	17.6x	22.3x	1.2x
Wed, 03 Apr 2024	€219.1b	€195.5b	€10.2b	17.2x	21.4x	1.1x
Fri, 01 Mar 2024	€219.9b	€194.9b	€10.2b	17.7x	21.6x	1.1x
Sun, 28 Jan 2024	€231.1b	€200.9b	€9.7b	19.1x	23.9x	1.2x
Tue, 26 Dec 2023	€228.6b	€202.7b	€12.9b	19x	17.8x	1.1x
Thu, 23 Nov 2023	€219.8b	€202.6b	€12.9b	18x	17.1x	1.1x
Sat, 21 Oct 2023	€204.4b	€207.2b	€12.4b	17.6x	16.5x	1x
Mon, 18 Sep 2023	€226.9b	€209.1b	€12.8b	18.8x	17.7x	1.1x
Wed, 16 Aug 2023	€219.7b	€209.0b	€12.9b	19.4x	17.1x	1.1x
Fri, 14 Jul 2023	€231.6b	€210.9b	€17.3b	18.6x	13.4x	1.1x
Sun, 11 Jun 2023	€241.0b	€210.8b	€17.3b	19.2x	13.9x	1.1x

Current Market PE

Investors are optimistic on the Finnish market, and appear confident in strong long term growth rates.

The market is trading at a PE ratio of 24.3x which is higher than its 3-year average PE of 20.1x.

Past Earnings Growth

The earnings for companies in the Finnish industry have declined 3.5% per year over the last three years.
Revenues have also declined 2.3% per year.
This means overall sales from these companies are declining and profits are subsequently falling as well.

Sector Trends

Which sectors have driven the changes within the Finnish Market?


FI Market	1.56%
Energy	9.92%
Tech	8.81%
Utilities	3.78%
Consumer Discretionary	-0.19%
Industrials	-0.62%
Materials	-0.87%
Consumer Staples	-1.77%
Financials	-2.86%
Telecom	-3.08%
Healthcare	-4.13%
Real Estate	-5.32%

Sector PE

Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 26.7x.

The market's confidence is likely because analysts are expecting annual earnings growth of 24.8% which is higher than its past year's earnings decline of 7.3% per year.

The Financials sector is the least preferred by investors for future growth, which is trading below its 3-year average of 16.2x.

Forecasted Growth

Analysts are most optimistic on the Real Estate sector, expecting annual earnings growth of 43% over the next 5 years.
This is better than its past earnings decline of 37% per year.

In contrast, the Utilities sector is expected to see its earnings grow by 3.1% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation	Sector
NOKIA Nokia Oyj	€14.81	9.9% +€7.5b	212.1%	PE107.3x	Tech
NESTE Neste Oyj	€30.02	9.9% +€2.1b	214.4%	PE32.2x	Energy
FORTUM Fortum Oyj	€21.12	3.8% +€690.9m	35.4%	PE23x	Utilities
HIAB Hiab Oyj	€60.35	13.3% +€458.1m	20.8%	PE28.9x	Industrials
METSO Metso Oyj	€16.29	0.8% +€107.7m	49.3%	PE28x	Industrials

Orion Pharma Announces First Results From Phase 1/2 TEADES Trial With TEAD Inhibitor ODM-212 In Patients With Advanced Solid Tumours

Orion Pharma announced first Phase 1 results from the ongoing Phase 1/2 multi-site, open-label, first-in-human TEADES trial evaluating the safety, tolerability and preliminary efficacy of ODM-212, a small molecule oral pan-TEAD inhibitor in patients with advanced solid tumours. According to the results, ODM-212 was well tolerated. Dose limiting toxicities (DLT) were not reported and the maximum tolerated dose (MTD) was not reached. The most frequent treatment-related adverse event (TRAE) was proteinuria (19.7%), which was reversible and resulted in treatment adjustment in 7.9% of patients. Other common TRAE’s were increased lipase (15.8%) and nausea (10.5%). Treatment responses by RECIST 1.1 were observed across multiple doses (overall response rate1, ORR 15.6%), predominantly in patients with mesothelioma (ORR 27.8%, disease control rate2, DCR 77.8%) and EHE (ORR 22.2%, DCR 100%). The new data were presented during the 2026 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, IL, United States, from May 29-June 2, 2026. Phase 2 of the TEADES trial is ongoing. The trial will enroll up to 300 patients with malignant pleural mesothelioma (MPM), EHE or other solid tumours with dysfunction in Hippo pathway, and who have progressed despite available standard treatments and with limited further treatment options. Another ongoing Phase 1/2 trial TEADCO is evaluating ODM-212 in combination with standard of care treatments in advanced mesothelioma, KRAS G12C mutated non-small cell lung cancer (NSCLC) and pancreatic cancer. The TEADES trial is a Phase 1/2 multi-center, open-label study that will enroll up to 300 patients with MPM, EHE or other solid tumours with dysfunction in Hippo pathway. The trial will include patients who have progressed despite available standard treatments and with limited further treatment options. The primary endpoints of the study are safety and tolerability with secondary endpoints including Overall Response Rate, Progression Free Survival and Overall Survival. This is a global trial conducted at oncology centers in the US and Europe. ODM-212 is an oral small-molecule pan-TEAD (Transcriptional Enhanced Associate Domain) inhibitor developed by Orion Pharma. It targets the Hippo signaling pathway, which regulates cell growth and organ size. Dysregulation of this pathway—particularly through YAP/TAZ activation—can lead to uncontrolled tumour growth and resistance to cancer therapies. ODM-212 works by blocking TEAD transcription factors, disrupting YAP-TEAD protein-protein interactions, and inhibiting TEAD auto-palmitoylation, which is essential for TEAD activity.

Finnish (OMX) Market Analysis & Valuation

Market Valuation and Performance

Sector Trends

Top Stock Gainers and Losers

Market Insights

Land of the rising yields 📈

Latest News

HIAB: Acquisition And Margin Execution Will Shape Balanced Fairly Valued Outlook

UPM: Future Returns Will Hinge On 2026 Cost Actions And Paper JV Execution

Nvidia Links With Nokia on AI and 5G as AI and Cloud Orders Top €1 Billion

Fortum Reports Higher Q1 Profits and Expands Renewable Projects With Swedish Hydropower Plan

Elisa Corporation Announces Nomination Board Changes

Sampo Announces €350 Million Share Buyback and Raises 2026 Underwriting Outlook

KNEBV: Elevated P/E Will Face Pressure From TK Elevator Deal Execution Risk

Orion Pharma Announces First Results From Phase 1/2 TEADES Trial With TEAD Inhibitor ODM-212 In Patients With Advanced Solid Tumours

NDA FI: Stablecoin Initiative And Dividend Policy Will Shape Balanced Outlook

Now 20% undervalued

BITTI: 2026 Earnings Guidance Will Underpin Rich P/E Despite Defence Contracts

METSO: Future Returns Will Depend On Lithium Progress And Dividend Reliability

Now 22% undervalued

Now 21% overvalued

Future Margin Targets And Mix Shift Will Likely Limit Long Term Upside

Results: Neste Oyj Exceeded Expectations And The Consensus Has Updated Its Estimates